Clinical burden of venous thromboembolism

Current Medical Research and Opinion

Volumn 26, Issue 10, 2010, Pages 2465-2473

  Ruppert, Andras ^a   Lees, Michael ^b   Steinle, Thomas ^c  

^a IMS Consulting   (United Kingdom)

^b Bayer Healthcare   (United Kingdom)

^c Amgen ^*  (Germany)

Author keywords

Anticoagulant; Pulmonary embolism; Thromboprophylaxis; Venous thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ANTIVITAMIN K; APIXABAN; DABIGATRAN ETEXILATE; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NONSTEROID ANTIINFLAMMATORY AGENT; RIVAROXABAN; WARFARIN;

ARTICLE; BLEEDING; CLINICAL ASSESSMENT; CLINICAL TRIAL; COCHRANE LIBRARY; DEEP VEIN THROMBOSIS; HEALTH CARE SYSTEM; HEPARIN INDUCED THROMBOCYTOPENIA; HIGH RISK PATIENT; HIGH RISK POPULATION; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; LUNG EMBOLISM; MEDLINE; MORBIDITY; MORTALITY; ORTHOPEDIC SURGERY; POSTTHROMBOSIS SYNDROME; PROPHYLAXIS; PULMONARY HYPERTENSION; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT; VENOUS THROMBOEMBOLISM;

COMORBIDITY; COST OF ILLNESS; HEALTH CARE COSTS; HOSPITALIZATION; HUMANS; INCIDENCE; ORTHOPEDIC PROCEDURES; POSTOPERATIVE COMPLICATIONS; VENOUS THROMBOEMBOLISM;

EID: 77956752875     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2010.516090     Document Type: Article

References (60)

1. Roumen-Klappe EM, den Heijer M, Janssen MC, et al. The post-thrombotic syndrome: incidence and prognostic value of non-invasive venous examinations in a six-year follow-up study. Thromb Haemost 2005;94:825-830
2. Spyropoulos A. Direct medical costs of venous thromboembolism and subsequent hospital readmission rates: an administrative claims analysis from 30 managed care organizations. J Manag Care Pharm 2007;13:475-486
3. Caprini JA, Botteman MF, Stephens JM, et al. Economic burden of long-term complications of deep vein thrombosis after total hip replacement surgery in the United States. Value Health 2003;6:59-74
4. Bergqvist D. Prolonged prophylaxis in postoperative medicine. Semin Thromb Hemost 1997;23:149-154
5. Sweetland S, Green J, Liu B, et al. Duration and magnitude of the postoperative risk of venous thromboembolism in middle aged women: prospective cohort study. BMJ 2009;339:b4583
6. Kearon C. Natural history of venous thromboembolism. Semin Vasc Med 2001;1:27-38
7. Kearon C. Natural history of venous thromboembolism. Circulation 2003; 107:I22-I30
8. Stein PD, Henry JW. Prevalence of acute pulmonary embolism among patients in a general hospital and at autopsy. Chest 1995;108:978-981
9. Leizorovicz A. Long-term consequences of deep vein thrombosis. Haemostasis 1998;28(Suppl. 3):1-7
10. Knight KK, Wong J, Hauch O, et al. Economic and utilization outcomes associated with choice of treatment for venous thromboembolism in hospitalized patients. Value Health 2005;8:191-200
11. Bullano MF, Willey V, Hauch O, et al. Longitudinal evaluation of health plan cost per venous thromboembolism or bleed event in patients with a prior venous thromboembolism event during hospitalization. J Manag Care Pharm 2005;11:663-673
12. O'Brien JA, Caro JJ. Direct medical cost of managing deep vein thrombosis according to the occurrence of complications. Pharmacoeconomics 2002; 20:603-615
13. Schulman S, Lindmarker P, Holmstrom M, et al. Post-thrombotic syndrome, recurrence, and death 10 years after the first episode of venous thrombo-embolism treated with warfarin for 6 weeks or 6 months. J Thromb Haemost 2006;4:734-742
14. Hansson PO, Sorbo J, Eriksson H. Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors. Arch Intern Med 2000;160:769-774
15. Friedman RJ. Optimal duration of prophylaxis for venous thromboembolism following total hip arthroplasty and total knee arthroplasty. J Am Acad Orthop Surg 2007;15:148-155
16. White RH, Romano PS, Zhou H, et al. Incidence and time course of throm-boembolic outcomes following total hip or knee arthroplasty. Arch Intern Med 1998;158:1525-1531
17. Bjornara BT, Gudmundsen TE, Dahl OE. Frequency and timing of clinical venous thromboembolism after major joint surgery. J Bone Joint Surg Br 2006;88:386-391
18. Ollendorf DA, Vera-Llonch M, Oster G. Cost of venous thromboembolism following major orthopedic surgery in hospitalized patients. Am J Health Syst Pharm 2002;59:1750-1754
19. Tilleul P, LaFuma A, Colin X, et al. Estimated annual costs of prophylaxis and treatment of venous thromboembolic events associated with major orthopedic surgery in France. Clin Appl Thromb Hemost 2006;12:473-484
20. Lopez JA, Kearon C, Lee AY. Deep venous thrombosis. Hematology Am Soc Hematol Educ Program 2004:439-456
21. Anderson Jr FA, Hirsh J, White K, et al. Temporal trends in prevention of venous thromboembolism following primary total hip or knee arthroplasty 1996-2001: findings from the Hip and Knee Registry. Chest 2003; 124:349S-56S
22. Arnold DM, Kahn SR, Shrier I. Missed opportunities for prevention of venous thromboembolism: an evaluation of the use of thromboprophylaxis guidelines. Chest 2001;120:1964-1971
23. Spencer FA, Lessard D, Emery C, et al. Venous thromboembolism in the outpatient setting. Arch Intern Med 2007;167:1471-1475
24. Friedman RJ, Gallus AS, Cushner FD, et al. Physician compliance with guidelines for deep-vein thrombosis prevention in total hip and knee arthroplasty. Curr Med Res Opin 2008;24:87-97
25. Schunemann HJ, Cook D, Grimshaw J, et al. Antithrombotic and thrombolytic therapy: from evidence to application: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:688S-96S (Pubitemid 39297968)
26. Warwick D, Dahl OE, Fisher WD. Orthopaedic thromboprophylaxis: limitations of current guidelines. J Bone Joint Surg Br 2008;90:127-132
27. Caprini JA, Hyers TM. Compliance with antithrombotic guidelines. Manag Care 2006;15:49-66
28. Kahn SR, Hirsch A, Shrier I. Effect of postthrombotic syndrome on health-related quality of life after deep venous thrombosis. Arch Intern Med 2002;162:1144-1148
29. Kahn SR. Frequency and determinants of the postthrombotic syndrome after venous thromboembolism. Curr Opin Pulm Med 2006;12:299-303
30. Prandoni P, Villalta S, Bagatella P, et al. The clinical course of deep-vein thrombosis. Prospective long-term follow-up of 528 symptomatic patients. Haematologica 1997;82:423-428
31. Kahn SR, Ginsberg JS. Relationship between deep venous thrombosis and the postthrombotic syndrome. Arch Intern Med 2004;164:17-26
32. Lee CH, Hankey GJ, Ho WK, et al. Venous thromboembolism: diagnosis and management of pulmonary embolism. Med J Aust 2005;182:569-574
33. Segal JB, Streiff MB, Hofmann LV, et al. Management of venous thrombo-embolism: a systematic review for a practice guideline. Ann Intern Med 2007;146:211-222
34. Trujillo-Santos J, Herrera S, Page MA, et al. Predicting adverse outcome in outpatients with acute deep vein thrombosis. Findings from the RIETE Registry. J Vasc Surg 2006;44:789-793
35. Stein PD, Kayali F, Beemath A, et al. Mortality from acute pulmonary embolism according to season. Chest 2005;128:3156-3158
36. Piazza G, Goldhaber SZ. Acute pulmonary embolism: part II: treatment and prophylaxis. Circulation 2006;114:e42-e47 (Pubitemid 44297102)
37. Peacock A, Simonneau G, Rubin L. Controversies, uncertainties and future research on the treatment of chronic thromboembolic pulmonary hypertension. Proc Am Thorac Soc 2006;3:608-614 (Pubitemid 44411628)
38. Pengo V, Lensing AW, Prins MH, et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med 2004; 350:2257-2264
39. Ulrich S, Fischler M, Speich R. Update on therapies for pulmonary hypertension. Swiss Med Wkly 2007;137:73-82
40. Vera-Llonch M, Hagiwara M, Oster G. Clinical and economic consequences of bleeding following major orthopedic surgery. Thromb Res 2006;117:569-577
41. Muntz J, Scott DA, Lloyd A, et al. Major bleeding rates after prophylaxis against venous thromboembolism: systematic review, meta-analysis, and cost implications. Int J Technol Assess Health Care 2004;20:405-414
42. Hitos K, Fletcher JP. Venous thromboembolism following primary total knee arthroplasty. Int Angiol 2006;25:343-351
43. Spencer FA, Gore JM, Lessard D, et al. Patient outcomes after deep vein thrombosis and pulmonary embolism: the Worcester Venous Thromboembolism Study. Arch Intern Med 2008;168:425-430
44. Warkentin TE. Think of HIT. Hematology Am Soc Hematol Educ Program 2006:408-414
45. De Maistre E, Gruel Y, Lasne D. Diagnosis and management of heparin-induced thrombocytopenia. Can J Anaesth 2006;53:S123-S134
46. Jang IK, Hursting MJ. When heparins promote thrombosis: review of heparin-induced thrombocytopenia. Circulation 2005;111:2671-2683
47. Hassell K. The management of patients with heparin-induced thrombocyto-penia who require anticoagulant therapy. Chest 2005;127:1S-8S
48. Warkentin TE, Greinacher A, Koster A, et al. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:340S-80S
49. Douketis JD, Gu CS, Schulman S, et al. The risk for fatal pulmonary embolism after discontinuing anticoagulant therapy for venous thromboembolism. Ann Intern Med 2007;147:766-774
50. Spencer FA, Emery C, Lessard D, et al. The Worcester Venous Thromboembolism study: a population-based study of the clinical epidemiology of venous thromboembolism. J Gen Intern Med 2006;21:722-727
51. Casais P, Meschengieser SS, Sanchez-Luceros A, et al. Patients' perceptions regarding oral anticoagulation therapy and its effect on quality of life. Curr Med Res Opin 2005;21:1085-1090
52. Ansell J, Jacobson A, Levy J, et al. Guidelines for implementation of patient self-testing and patient self-management of oral anticoagulation. International consensus guidelines prepared by International Self-Monitoring Association for Oral Anticoagulation. Int J Cardiol 2005;99:37-45
53. Douketis JD, Berger PB, Dunn AS, et al. The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133:299S-339S
54. Wofford JL, Wells MD, Singh S. Best strategies for patient education about anticoagulation with warfarin: a systematic review. BMC Health Serv Res 2008;8:40
55. Vinson DR, Berman DR, Patel PB, et al. Outpatient management of deep venous thrombosis: 2 models of integrated care. Am J Manag Care 2006; 12:405-410
56. Segal JB, Eng J, Tamariz LJ, et al. Review of the evidence on diagnosis of deep venous thrombosis and pulmonary embolism. Ann Fam Med 2007; 5:63-73
57. Bounameaux H. The novel anticoagulants: entering a new era. Swiss Med Wkly 2009;139:60-64
58. Haas S. New oral Xa and IIa inhibitors: updates on clinical trial results. J Thromb Thrombolysis 2008;25:52-60
59. Lassen MR, Laux V. Emergence of new oral antithrombotics: a critical appraisal of their clinical potential. Vasc Health Risk Manag 2008;4: 1373-1386
60. Laux V, Perzborn E, Heitmeier S, et al. Direct inhibitors of coagulation proteins-the end of the heparin and low-molecular-weight heparin era for anticoagulant therapy? Thromb Haemost 2009;102:892-899